Prince Andrew's firm linked to controversial PPE millionaire
After the prince's disastrous Newsnight interview in 2019, legal ownership of his Dragon's Den-style start-up competition, Pitch@Palace Global, was transferred to a Barrowman-linked firm, Knox House Trustees (UK).
Barrowman and his wife, lingerie boss Baroness Michelle Mone, hit the headlines when she admitted they had lied about their links to a company that won large government contracts during the Covid pandemic after she recommended it to ministers.
A lawyer for Mr Barrowman said he "at no time... had any business or personal involvement with the duke".
Pitch@Palace Global remained the prince's company, under his control. But in line with longstanding royal practice, it was owned under the names of other people or companies, acting on his behalf as so-called "nominees".
Documents filed at Companies House show that from 2021, the nominee owner was Knox House Trustees (UK), which was controlled and ultimately owned by Mr Barrowman until 2023.
Prince Andrew's finances have been under intense scrutiny, with questions about how he can afford to live in his Royal Lodge mansion in Windsor after he was cut off financially by his brother, King Charles.
The prince's choice of business associates has long been controversial. In December, he said he "ceased all contact" with Yang Tengbo, who led the Chinese arm of Pitch@Palace, after receiving advice from the UK government which alleged that he was a spy.
Mr Yang has denied being a spy or doing anything unlawful.
Mr Barrowman has attracted plenty of controversy too. In 2017, HMRC began an investigation into one of his companies, AML Tax (UK), which it said "aggressively promoted" tax avoidance schemes. It was fined £150,000 in 2022.
In January that year, the Guardian newspaper first reported links between Mr Barrowman, Baroness Mone and PPE Medpro. The pair denied involvement until December 2023, when she admitted in a BBC interview that they had lied about their links with the company.
The National Crime Agency is now investigating suspected criminal offences at the firm. Mr Barrowman and Baroness Mone both deny any wrongdoing.
Author Andrew Lownie, who is writing a biography of the prince, said: "Andrew has a long history of associating with dubious business figures and disguising his business activities behind nominee and offshore accounts. There really needs to be a full investigation into the duke's financial activities."
Pitch@Palace was a start-up competition, founded in 2014, where entrepreneurs would pitch their ideas to possible investors in the hope of winning their backing. It had two parts:
a UK-based version, set up as a community interest company, which cannot pay profits to shareholders
an international arm, Pitch@Palace Global Ltd, which held competitions in places such as Australia, Bahrain and China, and was set up as a for-profit UK company
Both arms of Pitch@Palace suspended operations following the Newsnight interview in 2019 about the prince's links to the late sex offender Jeffrey Epstein, which led to Andrew stepping down as a working royal.
Nonetheless, the international operation has emerged as a possible way for the duke to fund his lifestyle. In a court witness statement from 2023, Mr Yang wrote that the duke had needed money "and saw the relationships with China through Pitch as one possible source of funding".
Earlier this year a Dutch company said it was in talks to buy it, saying it saw "immense value" in the network, even though it had suspended operations.
However, Prince Andrew has never held the company in his own name.
Founded in 2017, Pitch@Palace Global Ltd was initially held in the name of Amanda Thirsk, the prince's private secretary, in an arrangement often used by the Royal Family.
But early in 2021, the legal ownership was transferred to Knox House Trustees (UK) Limited.
This company had been set up the year before, and Mr Barrowman was named as having "significant influence and control" over it.
Corporate filings in the Isle of Man show Knox House Trustees (UK) was ultimately owned by Knox Limited, whose sole shareholder is Mr Barrowman.
In 2023, ownership of Knox House Trustees (UK) Ltd – which still owned Pitch@Palace Global - was transferred to Arthur Lancaster, an accountant who has a longstanding working relationship with both the prince and Mr Barrowman. This remains the situation today.
The same year Mr Lancaster took over as the sole director and shareholder of PPE Medpro. He was also a director of many of the companies involved in the AML tax avoidance case.
The judge in that case called him "evasive" and said he had "real concerns as to the reliability of Mr Lancaster's evidence", which contained "significant inconsistencies".
After the case, his lawyer wrote to the court arguing that the conclusions were "unnecessarily harsh", that Mr Lancaster had been a "diligent and truthful witness", and that his efforts to provide information had been hampered by the Covid pandemic.
For decades the Royal Family has held investments through nominees, and still does. In the past this has served to keep details of their holdings private, though not in this case. Prince Andrew's involvement in Pitch@Palace Global is well known, and he is listed as having "significant influence or control" over the company on Companies House.
Mr Barrowman's lawyer said in a statement: "Mr Lancaster was a director of KHT (UK) Ltd which provided company administration services to a number of external companies, including Pitch@Palace, a company wholly owned by the duke. Mr Lancaster acted for the duke in a personal capacity at all times and has been an associate of the duke for many years."
Mr Lancaster declined to comment. Prince Andrew did not respond to requests for comment.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
40 minutes ago
- Yahoo
'We support the status quo': Australia's Albanese on Taiwan
STORY: :: Anthony Albanese says Australia 'supports the status quo' on Taiwan during his China visit :: July 13, 2025 :: Shanghai, China :: Anthony Albanese, Australian Prime Minister "I think it's important that we have a consistent position which Australia has had for a long period of time. We support the status quo when it comes to Taiwan, we don't support any unilateral action there. We have a clear position, and we have been consistent about that. What's important when it comes to international relationships is that you have a stable, orderly, coherent position going forward. Australia does. We want peace and security in our region. We don't want any change to the status quo. That's Australia's position today. That was Australia's position last week. That's been a bipartisan position for a long period of time." The Financial Times reported on Saturday (July 12) that Elbridge Colby, the U.S. under-secretary of defense for policy, has been pushing Australian and Japanese officials on what they would do in a Taiwan conflict, although the U.S. does not offer a blank check guarantee to defend Taiwan. China claims democratically governed Taiwan as its own and has not ruled out the use of force to bring Taiwan under its control. Taiwan President Lai Ching-te rejects China's sovereignty claims, saying only Taiwan's people can decide their future. Security is expected to be on the agenda when Albanese meets China's leaders this week. After his arrival in Shanghai, Albanese watched on as Tourism Australia and Group signed a memorandum of understanding that will promote Australia as a premier tourist destination for Chinese travelers.
Yahoo
an hour ago
- Yahoo
Bayer Wins Hormone-Free Treatment Approval for Women in the UK
Bayer BAYRY announced that it has won approval for pipeline drug elinzanetant in the UK for the treatment of moderate to severe vasomotor symptoms (VMS or hot flashes) associated with menopause. The Medicines and Healthcare products Regulatory Agency, a regulatory authority in the UK, has authorized the use of elinzanetant, under the brand name Lynkuet for the above-mentioned indication. Year to date, shares of Bayer have rallied 67% compared to the industry's gain of 2.7%. Image Source: Zacks Investment Research Elinzanetant is the first dual neurokinin (NK)-targeted therapy (NK-1 and NK- 3 receptor antagonist), which has been globally developed for the treatment of moderate to severe VMS associated with menopause or endocrine therapy for breast cancer, administered orally once daily. The marketing authorization in the UK marks the drug's first global approval. The approval was based on positive results from the late-stage studies OASIS-1, OASIS-2, and OASIS-3, which evaluated the efficacy and safety profile of elinzanetant. Results from the study showed that elinzanetant met all primary endpoints in all three studies and demonstrated a favorable safety profile. We note that elinzanetant is under regulatory review in the United States, countries of the European Union and other markets around the world. The approval of this hormone-free treatment is not only a transformative therapeutic advance for millions of women worldwide but also a compelling growth catalyst for Bayer's pharmaceutical division. As the first drug targeting both NK-1 and NK-3 receptors, it sidesteps the risks and contraindications associated with estrogen therapy, making it an attractive option for millions, including breast cancer survivors or women avoiding hormone-based interventions. Bayer's new products, such as Nubeqa and Kerendia, continue to maintain their impressive momentum in the Pharmaceutical division and offset the negative impact of a decline in Xarelto sales. The company is working to expand the labels of these key drugs, which should boost its top-line growth. Last month, the FDA expanded Nubeqa's label for a third indication for patients with advanced prostate cancer. The successful development of additional drugs is imperative for Bayer amid multiple challenges. BAYRY expects to launch two new drugs — elinzanetant and acoramidis, a drug for the treatment of a certain type of heart disease. The company also aims to strengthen its pharmaceutical pipeline. In 2021, Bayer acquired a clinical-stage biopharmaceutical company, Vividion Therapeutics, to expand into precision small-molecule therapeutics, primarily in oncology and immunology. BAYRY has expanded its pipeline in new modalities of cell therapy through the acquisition of BlueRock, and in gene therapy, through the AskBio buyout. BAYRY currently carries a Zacks Rank #1 (Strong Buy). A couple of other top-ranked stocks in the large-cap pharma sector are Novartis NVS and Johnson & Johnson JNJ, both carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today's Zacks #1 Rank stocks here. The Zacks Consensus Estimate for Novartis' 2025 earnings per share (EPS) has risen from $8.78 to $8.92 over the past 60 days. EPS estimates for 2026 have jumped 20 cents to $9.27 during the said timeframe. The stock has risen 30.2% so far this year. J&J's EPS estimate for 2025 has risen from $10.60 to $10.64 over the past 60 days, while that for 2026 has increased from $10.98 to $11.07 over the same timeframe. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Novartis AG (NVS) : Free Stock Analysis Report Johnson & Johnson (JNJ) : Free Stock Analysis Report Bayer Aktiengesellschaft (BAYRY) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Bloomberg
an hour ago
- Bloomberg
UK Plans New Measure to Boost EV Sales, Transport Secretary Says
The UK plans to introduce new incentives to make it cheaper for people to buy new electric vehicles as the Labour government attempts to phase out the sale of polluting cars. Speaking on Sunday, Transport Secretary Heidi Alexander confirmed she will be announcing new measures to boost sales of EVs this week but declined to directly address reports in the Telegraph and the Times that the incentives will include up to £700 million ($948 million) in new subsidies and grants to buyers to help offset costs.